

Author Relationships With Industry and Other Entities (Comprehensive)—2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease (February 2015)

Committee Member	Employer/Title	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational or Other Financial Benefit	Expert Witness
Glenn N. Levine (Chair)	Baylor College of Medicine—Professor of Medicine; Director, Cardiac Care Unit	None	None	None	None	None	• Defendant, ECG interpretation, 2014
Eric R. Bates (Vice Chair, PCI)	University of Michigan—Professor of Medicine	• AstraZeneca • Merck	None	None	• Harvard Clinical Research Institute (DSMB)	• ABIM • AHA*	None
John A. Bittl	Munroe Regional Medical Center—Interventional Cardiologist	None	None	None	None	None	None
Ralph G. Brindis	University of California, San Francisco—Philip R. Lee Institute for Health Policy Studies—Clinical Professor of Medicine	None	• Volcano Corp	None	• Harvard Clinical Research Institute (DAPT trial (Advisory Board)) • C-PORT Elective (DSMB)	• CA Elective PCI Project (DSMB) • CA State Board OSHPD • FDA CV Device Panel	None
Stephan D. Fihn (Chair, SIHD)	Department of Veterans Affairs—Director, Office of Analytics and Business Intelligence	None	None	None	None	None	None
Lee A. Fleisher (Chair, Periop)	University of Pennsylvania, Department of Anesthesiology—Professor of Anesthesiology	• Blue Cross/Blue Shield Association-Medical Advisory Panel to the Technology Evaluation Center† • National Quality Forum*	None	None	• Johns Hopkins Medical Institutions (DSMB) • NIH	• Association of University Anesthesiologists*	None
Christopher B. Granger	Duke Clinical Research Institute—Director, Cardiac Care Unit; Professor of Medicine	• Armethreon • AstraZeneca • Bayer • Boehringer Ingelheim†	None	None	• Armethreon† • AstraZeneca† • Bayer† • Boehringer-	• GE† • Medtronic† • Phillips† • Spacelabs†	None

		<ul style="list-style-type: none"> • Bristol-Myers Squibb† • Daiichi-Sankyo • Gilead Sciences • GlaxoSmithKline • Hoffman LaRoche • Janssen Pharmaceuticals • Medtronic • Pfizer • Ross Medical • Salix Pharmaceuticals • Sanofi-aventis • Eli Lilly • The Medicines Company 			<ul style="list-style-type: none"> • Ingelheim† • Bristol-Myers Squibb† • Daiichi-Sankyo† • GlaxoSmithKline† • Janssen Pharmaceuticals† • Medtronic† • Merck† • Pfizer • Sanofi-aventis† • Takeda† • The Medicines Company† 	<ul style="list-style-type: none"> • Zoll† 	
Richard A. Lange	Texas Tech University Health Sciences Center El Paso—President; Paul L. Foster School of Medicine—Dean	None	None	None	• None	None	None
Michael J. Mack	The Heart Hospital Baylor—Director	None	None	None	<ul style="list-style-type: none"> • Abbott Vascular* • Edwards LifeSciences* 	None	None
Laura Mauri	Brigham & Women's Hospital—Professor of Medicine, Harvard Medical School	<ul style="list-style-type: none"> • Biotronik • Medtronic • St. Jude Medical 	None	None	<ul style="list-style-type: none"> • Abbott† • Boston Scientific† • Bristol-Myers Squibb† • Cordis† • Daiichi-Sankyo† • Eli Lilly† • Medtronic Cardiovascular† • Sanofi-aventis† 	<ul style="list-style-type: none"> • ABIM 	None
Roxana Mehran	Mount Sinai Medical Center—Professor of Medicine	<ul style="list-style-type: none"> • Abbott • AstraZeneca • Biosenor • Boston Scientific • Covidien 	None	<ul style="list-style-type: none"> • Wiley Blackwell Publishing (Royalty) 	<ul style="list-style-type: none"> • Lilly/DSI* • NHLBI • STENTYS* 	<ul style="list-style-type: none"> • SCAI* • WebMD 	None

		<ul style="list-style-type: none"> • Johnson & Johnson • Merck • Osprey† • Regado • The Medicines Company 					
Debabrata Mukherjee	Texas Tech University— Chief, Cardiovascular Medicine	None	None	None	None	• ACC	None
L. Kristin Newby	Duke University Medical Center, Division of Cardiology—Professor of Medicine	<ul style="list-style-type: none"> • BioKier • CAMC Health Education and Research Institute • Cubist/INC Research • JAHA • Janssen Pharmaceuticals • MedScape/ TheHeart.org • MetroHealth System • Merck • Philips • Roche • VoxMedia 	None	None	<ul style="list-style-type: none"> • Amylin • Bristol-Myers Squibb† • GlaxoSmithKline† • Google Life Sciences • Duke Medicine† • NIH • PCORI† 	<ul style="list-style-type: none"> • ACP • AHA* • AstraZeneca* • Society of Chest Pain Centers 	None
Patrick T. O’Gara, (Chair, STEMI)	Harvard Medical School—Professor of Medicine	None	None	None	• NIH	None	None
Marc S. Sabatine	Brigham and Women's Hospital, Chairman— TIMI Study Group, Division of Cardiovascular Medicine; Harvard Medical School— Professor of Medicine	<ul style="list-style-type: none"> • Amgen† • AstraZeneca† • Cubist • CVS Caremark • Intarcia† • Medscape† • Merck • MyoKardia • Pfizer • Sanofi-aventis • Vox Media† 	None	None	<ul style="list-style-type: none"> • Abbott† • Amgen† • AstraZeneca† • Critical Diagnostics† • Daiichi-Sankyo† • Eisai† • Gilead† • GlaxoSmithKline† • Intarcia† • Merck† 	<ul style="list-style-type: none"> • Abbott† • AstraZeneca† • Athera† • BRAHMS† • GlaxoSmithKline† • Merck† • Muljibhai Patel Society for Research in Nephro-Urology† • Singulex† 	None

		• Zeus Scientific			• NIH† • Roche Diagnostics† • Sanofi-aventis† • Takeda†	• Takeda†	
Peter K. Smith (Vice Chair, CABG)	Duke University Medical Center—Professor of Surgery; Chief, Thoracic Surgery	None	None	None	None	None	None
Sidney C. Smith, Jr (Chair, Secondary Prevention)	University of North Carolina—Professor of Medicine; Center for Cardiovascular Science and Medicine—Director	None	None	None	None	None	None

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of $\geq 5\%$ of the voting stock or share of the business entity, or ownership of $\geq \$5,000$ of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

*No financial benefit.

†Significant relationship.

ABIM indicates American Board of Internal Medicine; ACC, American College of Cardiology; ACCF, American College of Cardiology Foundation; ACP, American College of Physicians; AHA, American Heart Association; AMA, American Medical Association; DAPT, dual antiplatelet therapy; DSMB, data safety monitoring board; ECG, electrocardiogram; JAHA, Journal of the American Heart Association; NCDR, National Cardiovascular Data Registry; NHLBI, National Heart, Lung, and Blood Institute; NIH, National Institutes of Health; SCAI, Society for Cardiovascular Angiography and Interventions; and TIMI, Thrombosis In Myocardial Infarction.